Evidence-Based Guidelines for Cardiovascular Disease Prevention
... search were similar to those for the research conducted in 2003 and described previously (9). The time period for the updated search was January 2003 through June 7, 2006. New topics were searched electronically on 3 databases from their inception (Medline, 1966 through June 7, 2006; CINAHL, 1982 th ...
... search were similar to those for the research conducted in 2003 and described previously (9). The time period for the updated search was January 2003 through June 7, 2006. New topics were searched electronically on 3 databases from their inception (Medline, 1966 through June 7, 2006; CINAHL, 1982 th ...
left bundle branch block significance
... resynchronization therapy (CRT) (5-11). LBBB provides prognostic information (5), but it also poses challenges in therapeutic management (3,6). Cardiovascular pathology, represented particularly by the coronary artery disease, has become a pandemic disease of this century, with an increased incidenc ...
... resynchronization therapy (CRT) (5-11). LBBB provides prognostic information (5), but it also poses challenges in therapeutic management (3,6). Cardiovascular pathology, represented particularly by the coronary artery disease, has become a pandemic disease of this century, with an increased incidenc ...
this PDF file
... caused bleeding by prolonging the prothrombin time13,14. However, even low doses of aspirin which did not affect the prothrombin time prevented coronary thrombosis12. Because aspirin in high doses was associated with bleeding, many physicians in 1940s were prescribing aspirin together with vitamin K ...
... caused bleeding by prolonging the prothrombin time13,14. However, even low doses of aspirin which did not affect the prothrombin time prevented coronary thrombosis12. Because aspirin in high doses was associated with bleeding, many physicians in 1940s were prescribing aspirin together with vitamin K ...
Brilinta - PI
... In clinical trials, about 14% of patients treated with BRILINTA developed dyspnea. Dyspnea was usually mild to moderate in intensity and often resolved during continued treatment, but led to study drug discontinuation in 0.9% of BRILINTA and 0.1% of clopidogrel patients in PLATO and 4.3% of BRILINTA ...
... In clinical trials, about 14% of patients treated with BRILINTA developed dyspnea. Dyspnea was usually mild to moderate in intensity and often resolved during continued treatment, but led to study drug discontinuation in 0.9% of BRILINTA and 0.1% of clopidogrel patients in PLATO and 4.3% of BRILINTA ...
Ventricular Relaxation and Diastolic Chamber Stiffness Induced by
... pressure and volume in the coronary vasculature may be one determinant of ventricular diastolic compliance (18-20). To further isolate the potential effects of coronary vasodilatation and engorgement of the ventricular wall (erectile effect), the change in ventricular diastolic pressure during hypox ...
... pressure and volume in the coronary vasculature may be one determinant of ventricular diastolic compliance (18-20). To further isolate the potential effects of coronary vasodilatation and engorgement of the ventricular wall (erectile effect), the change in ventricular diastolic pressure during hypox ...
hyperbaric oxygen therapy for acute coronary syndrome
... countries, and is predicted to become the disease with the greatest global burden by 2020 (WHO 2003). In the United Kingdom, coronary heart disease is the most common cause of premature death, causing 125,000 deaths from approximately 274,000 episodes in 2000, and at a community cost of around UKP10 ...
... countries, and is predicted to become the disease with the greatest global burden by 2020 (WHO 2003). In the United Kingdom, coronary heart disease is the most common cause of premature death, causing 125,000 deaths from approximately 274,000 episodes in 2000, and at a community cost of around UKP10 ...
Stable Angina and If Inhibition: New Insights and
... symptoms, and in patients with extensive ischemia, like those with left main or three-vessel disease, also improves prognosis. Effective restoration of adequate coronary flow, either surgical or percutaneous, does not obviate the need for medical treatment. Medical therapy is necessary to prevent su ...
... symptoms, and in patients with extensive ischemia, like those with left main or three-vessel disease, also improves prognosis. Effective restoration of adequate coronary flow, either surgical or percutaneous, does not obviate the need for medical treatment. Medical therapy is necessary to prevent su ...
Slides - Clinical Trial Results
... • Re-infarction • Unplanned target lesion revascularisation (TLR) ...
... • Re-infarction • Unplanned target lesion revascularisation (TLR) ...
Update on Statins
... Earlier secondary-prevention statin studies established a statin benefit on stroke risk. In HPS, stroke was also significantly reduced by 25% (P⬍0.0001).31 Although the absolute stroke rates in these clinical trials were small, these studies showed that statin therapy decreased ischemic stroke witho ...
... Earlier secondary-prevention statin studies established a statin benefit on stroke risk. In HPS, stroke was also significantly reduced by 25% (P⬍0.0001).31 Although the absolute stroke rates in these clinical trials were small, these studies showed that statin therapy decreased ischemic stroke witho ...
Anti platelet Agents
... uncontrolled progression of such a process through a series of self-sustaining amplification loops may lead to intraluminal thrombus formation, vascular occlusion and transient ischaemia or infarction. Currently available antiplatelet drugs interfere with some steps in the activation process, includ ...
... uncontrolled progression of such a process through a series of self-sustaining amplification loops may lead to intraluminal thrombus formation, vascular occlusion and transient ischaemia or infarction. Currently available antiplatelet drugs interfere with some steps in the activation process, includ ...
Document
... The pharmacodynamic interaction between clopidogrel and PPIs and the initial findings from observational studies suggested an increased risk of cardiovascular events in concomitant users of clopidogrel and PPIs. Recently published data from a randomized clinical trial suggest that this risk is likel ...
... The pharmacodynamic interaction between clopidogrel and PPIs and the initial findings from observational studies suggested an increased risk of cardiovascular events in concomitant users of clopidogrel and PPIs. Recently published data from a randomized clinical trial suggest that this risk is likel ...
Congenital abnormalities of aortic artery. Assessment in neonates
... It is defined as the loss of anatomic continuity between the ascending and the descending aorta, and it is considered as an extreme form of coarctation. The flow towards the descending aorta is given by the ductus, which remains permeable and provides continuity between the trunk of the pulmonary ar ...
... It is defined as the loss of anatomic continuity between the ascending and the descending aorta, and it is considered as an extreme form of coarctation. The flow towards the descending aorta is given by the ductus, which remains permeable and provides continuity between the trunk of the pulmonary ar ...
Evaluation and Management of the Patient Who Has Cocaine-associated Chest Pain ,
... can occur in patients who have cocaine-associated myocardial infarction (MI) whether or not underlying coronary artery disease is present [2,22]. Chronic users of cocaine may be prone to early atherosclerosis, as demonstrated by autopsy studies of young cocaine users [27–29]. Although initial report ...
... can occur in patients who have cocaine-associated myocardial infarction (MI) whether or not underlying coronary artery disease is present [2,22]. Chronic users of cocaine may be prone to early atherosclerosis, as demonstrated by autopsy studies of young cocaine users [27–29]. Although initial report ...
Visualization and quantification of myocardial mass at risk using
... injections are used. Another benefit of an agent with a resistant microcapsule shell is pressure insensitivity. Previously used contrast agents are destroyed by diagnostic acoustic pressures. This results in unreliable myocardial opacification, especially if its longer persistence is required as is ...
... injections are used. Another benefit of an agent with a resistant microcapsule shell is pressure insensitivity. Previously used contrast agents are destroyed by diagnostic acoustic pressures. This results in unreliable myocardial opacification, especially if its longer persistence is required as is ...
Treatment in Acute MI
... The magnitude of platelet activation is associated with an increased risk for adverse clinical events after coronary intervention ...
... The magnitude of platelet activation is associated with an increased risk for adverse clinical events after coronary intervention ...
S193687981401646X_mmc1
... before high-risk PCI. Those in CS, within 48 hours of MI, with contraindication to IABP or with class I indications for IABP therapy were excluded ...
... before high-risk PCI. Those in CS, within 48 hours of MI, with contraindication to IABP or with class I indications for IABP therapy were excluded ...
Correlation Between ST‐Segment Elevation and Negative T Waves
... RV, such as leads V1 , III, and/or V2 –V4 . When the RV is dilated, the leads V2 –V3 and even V4 will be adjacent to the RV. Second, patency of the coronary arteries was confirmed in part of the patients showing STE in these leads. In our cases, coronary angiography showed only slight atherosclerosi ...
... RV, such as leads V1 , III, and/or V2 –V4 . When the RV is dilated, the leads V2 –V3 and even V4 will be adjacent to the RV. Second, patency of the coronary arteries was confirmed in part of the patients showing STE in these leads. In our cases, coronary angiography showed only slight atherosclerosi ...
percutaneous coronary intervention in patients with atrial
... risk of major bleeding (I). Uninterrupted warfarin treatment did not increase perioperative complications and seemed to decrease bleeding complications compared to heparin bridging (II). Already mild renal impairment (eGFR 60– 90mL/min) was associated with a 2.3‐fol ...
... risk of major bleeding (I). Uninterrupted warfarin treatment did not increase perioperative complications and seemed to decrease bleeding complications compared to heparin bridging (II). Already mild renal impairment (eGFR 60– 90mL/min) was associated with a 2.3‐fol ...
Morphine reduces the threshold of remote ischemic preconditioning
... the ischemia response and its modulation by these treatments. Secondly, as observed in the current investigation, remote ischemic preconditioning previously was shown to be dependent on the number of brief exposure episodes induced before left coronary artery ischemia and reperfusion. Whether exposu ...
... the ischemia response and its modulation by these treatments. Secondly, as observed in the current investigation, remote ischemic preconditioning previously was shown to be dependent on the number of brief exposure episodes induced before left coronary artery ischemia and reperfusion. Whether exposu ...
update on antiplatelet therapy in the treatment and prevention
... A randomized, double-blind placebo controlled trial of 15,603 patients (79% ) with established CVD and 21% with multiple risk factors designed to test whether clopidogrel should be continued beyond 1 year in addition to aspirin. All patients received daily aspirin(75-162mg) and were randomized to da ...
... A randomized, double-blind placebo controlled trial of 15,603 patients (79% ) with established CVD and 21% with multiple risk factors designed to test whether clopidogrel should be continued beyond 1 year in addition to aspirin. All patients received daily aspirin(75-162mg) and were randomized to da ...
Cardiac Catheterization History and Current Practice Standards
... condition, define its anatomic and physiologic severity, and determine the presence or absence of associated conditions when a therapeutic intervention is planned in a symptomatic patient. The most common indication for cardiac catheterization today thus consists of a patient with an acute coronary i ...
... condition, define its anatomic and physiologic severity, and determine the presence or absence of associated conditions when a therapeutic intervention is planned in a symptomatic patient. The most common indication for cardiac catheterization today thus consists of a patient with an acute coronary i ...
ACCF/ACR/SCCT/SCMR/ ASNC/NASCI/SCAI/SIR Appropriateness
... CMR and related resources. Our approach is not to diminish the acknowledged ambiguity of clinical decision making for certain patients by statistical means or consensus techniques, but to recognize that real differences in clinical opinion can exist for particular patient presentation, especially in ...
... CMR and related resources. Our approach is not to diminish the acknowledged ambiguity of clinical decision making for certain patients by statistical means or consensus techniques, but to recognize that real differences in clinical opinion can exist for particular patient presentation, especially in ...
ACCF/ACR/SCCT/SCMR - מכון הדימות The Division of Diagnostic
... and systematically create, review, and categorize appropriateness criteria for cardiovascular diagnostic tests and procedures utilized by physicians caring for patients with cardiovascular diseases. The ACCF believes that a careful blending of a broad range of clinical experience and available evide ...
... and systematically create, review, and categorize appropriateness criteria for cardiovascular diagnostic tests and procedures utilized by physicians caring for patients with cardiovascular diseases. The ACCF believes that a careful blending of a broad range of clinical experience and available evide ...
Secondary Prevention CVD
... • Adding plant stanol/sterols (2 g/d) and viscous fiber (⬎10 g/d) will further lower LDL-C. • Promote daily physical activity and weight management. I (B) • Encourage increased consumption of omega-3 fatty acids in the form of fish‡ or in capsule form (1 g/d) for risk reduction. For treatment of ele ...
... • Adding plant stanol/sterols (2 g/d) and viscous fiber (⬎10 g/d) will further lower LDL-C. • Promote daily physical activity and weight management. I (B) • Encourage increased consumption of omega-3 fatty acids in the form of fish‡ or in capsule form (1 g/d) for risk reduction. For treatment of ele ...
Guideline on the management of bleeding in patients on
... 2002). Bivalirudin activity may be monitored by ACT or by APTT. The PT is minimally prolonged at therapeutic bivalirudin concentrations. The pharmacology and clinical applications of bivalirudin have been reviewed recently (Warkentin et al, 2008). Given the short plasma half-life of bivalirudin, ces ...
... 2002). Bivalirudin activity may be monitored by ACT or by APTT. The PT is minimally prolonged at therapeutic bivalirudin concentrations. The pharmacology and clinical applications of bivalirudin have been reviewed recently (Warkentin et al, 2008). Given the short plasma half-life of bivalirudin, ces ...
Drug-eluting stent
A drug-eluting stent (DES) is a peripheral or coronary stent (a scaffold) placed into narrowed, diseased peripheral or coronary arteries that slowly releases a drug to block cell proliferation. This prevents fibrosis that, together with clots (thrombi), could otherwise block the stented artery, a process called restenosis. The stent is usually placed within the peripheral or coronary artery by an interventional cardiologist or interventional radiologist during an angioplasty procedure.Drug-eluting stents in current clinical use were approved by the FDA after clinical trials showed they were statistically superior to bare-metal stents for the treatment of native coronary artery narrowings, having lower rates of major adverse cardiac events (usually defined as a composite clinical endpoint of death + myocardial infarction + repeat intervention because of restenosis). The first drug-eluting stents to be approved in Europe and the U.S. were coated with paclitaxel or an mTOR inhibitor, such as sirolimus.